Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.32 |
| ▸ | SCN1A | P35498 | 2/20 | 0.32 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
| ▸ | KIF18A | Q8NI77 | 5/20 | 0.31 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22323445 | 0.95 | RBP4 (0.33) | TACR1CYP3A4SCN9APTPN11SCN1A | |
| SCHEMBL22323193 | 0.92 | SCN9A (0.37) | TACR1CYP3A4SCN9APTPN11SCN1A | |
| SCHEMBL22323413 | 0.92 | SCN9A (0.33) | TACR1CYP3A4SCN9APTPN11SCN1A | |
| SCHEMBL22323184 | 0.92 | CYP3A4 (0.34) | TACR1CYP3A4SCN9APTPN11SCN1A | |
| SCHEMBL22323191 | 0.91 | CYP3A4 (0.41) | TACR1CYP3A4SCN9APTPN11SCN1A | |
| SCHEMBL22323148 | 0.91 | SCN9A (0.32) | TACR1CYP3A4SCN9ASCN1ASCN8A | |
| SCHEMBL22323423 | 0.91 | SCN9A (0.32) | TACR1CYP3A4SCN9ASCN1ASCN8A | |
| SCHEMBL22323146 | 0.91 | SCN9A (0.32) | TACR1CYP3A4SCN9ASCN1ASCN8A | |
| SCHEMBL22323141 | 0.91 | CYP3A4 (0.36) | TACR1CYP3A4SCN9APTPN11SCN1A | |
| SCHEMBL22323452 | 0.90 | SCN9A (0.33) | TACR1CYP3A4SCN9ASCN1ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2022-04-28 | — | — | US | claimed |
| EP-3921313-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2021-12-15 | — | — | EP | claimed |
| CN-113423702-A | N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use in the treatment of disease | 诺华股份有限公司 | 2021-09-21 | — | — | CN | claimed |
| WO-2020161623-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2020-08-13 | — | — | WO | claimed |
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2022-04-28 | — | — | US | disclosed |
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2022-04-28 | — | — | US | disclosed |
| EP-3921313-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2021-12-15 | — | — | EP | disclosed |
| CN-113423702-A | N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use in the treatment of disease | 诺华股份有限公司 | 2021-09-21 | — | — | CN | disclosed |
| WO-2020161623-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | CFTR, P2RY1, P2RX5 | TACR1 423/4885CYP3A4 1068/4885SCN9A 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.